Table 1: Clinical Trials of AmplimexonŽ

Protocol No.
Phase
Combination with
Target
Status
Results
AMP-001
I
None

Metastatic Cancer

Completed
Response In Lymphoma
AMP-011
I
None
Metastatic Cancer
Completed
MTD Established
AMP-007
I
None
Multiple Myeloma
Completed
No Responses
AMP-005
I/II
DTIC
Malignant Melanoma
Completed
Prolonged Survival
AMP-004
I
Gemzar
Pancreatic Cancer
Completed
Responses Noted
AMP-010
I
Taxotere
Lung, Breast, Prostate Cancer
Completed
Responses In Lung and Prostate
AMP-019
II
Gemzar
Pancreatic Cancer
Ongoing
Survival Endpoint early 2010
AMP-024
II
Taxotere
Lung Cancer
Planned
-
AMP-008
II
DTIC
Malignant Melanoma
Planned
-